FDA Approves Tzield for Stage 3 Type 1 Diabetes in Adolescents

Event summary

  • FDA approves Tzield for use in individuals aged 8-17 within eight weeks of a stage 3 T1D diagnosis.
  • Tzield is the first disease-modifying therapy approved for stage 3 T1D, following prior approval for stage 2 T1D in 2022.
  • The PROTECT study demonstrated Tzield's ability to preserve beta cell function and delay disease progression.
  • Sanofi's confirmatory BETA-PRESERVE study will provide additional data on Tzield's efficacy in the coming years.

The big picture

The FDA's approval of Tzield for stage 3 T1D marks a significant milestone in the treatment of type 1 diabetes, offering the first disease-modifying therapy for this stage. This approval not only reinforces the importance of beta cell preservation but also sets a precedent for future therapies relying on C-peptide as a clinical trial endpoint. The strategic collaboration between Breakthrough T1D and Sanofi, along with ongoing clinical studies, positions Tzield as a cornerstone in the evolving landscape of T1D treatment.

What we're watching

Regulatory Pathway
How the approval of Tzield for stage 3 T1D will influence the regulatory pathway for other disease-modifying therapies in the T1D pipeline.
Clinical Data
The pace at which Sanofi's BETA-PRESERVE study will provide confirmatory data on Tzield's long-term efficacy and safety.
Market Expansion
Whether Breakthrough T1D can leverage this approval to expand Tzield's availability globally for stage 3 T1D patients.